UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 88

Sortiert nach

Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders

Lancet neurology, 2022-02, Vol.21 (2), p.176-188

2022

Volltextzugriff (PDF)

Inflammatory and anti-inflammatory markers in plasma: from late pregnancy to early postpartum

Scientific reports, 2019-02, Vol.9 (1), p.1863, Article 1863

2019

Volltextzugriff (PDF)

Cancer in myasthenia gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies: A Swedish nationwide register study

European journal of neurology, 2021-05, Vol.28 (5), p.1706-1715

2021

Volltextzugriff (PDF)

Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study

Clinical neurophysiology, 2021-07, Vol.132 (7), p.1733-1740

2021

Volltextzugriff (PDF)

Functional imaging of conduction dynamics in cortical and spinal axons

eLife, 2023-08, Vol.12

2023

Volltextzugriff (PDF)

Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal

European journal of neurology, 2023-01, Vol.30 (1), p.266-282

2023

Volltextzugriff (PDF)

Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine

Frontiers in immunology, 2020-03, Vol.11, p.213-213

2020

Volltextzugriff (PDF)

Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance‐based measures: A pilot study

Muscle & nerve, 2017-08, Vol.56 (2), p.207-214

2017

Volltextzugriff (PDF)

Epidemiology of Myasthenia Gravis in Sweden 2006–2016

Brain and behavior, 2020-11, Vol.10 (11), p.e01819-n/a

2020

Volltextzugriff (PDF)

Myasthenia gravis patient and physician opinions about immunosuppressant reduction

Muscle & nerve, 2020-06, Vol.61 (6), p.767-772

2020

Volltextzugriff (PDF)

Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients

Scientific reports, 2017-01, Vol.7 (1), p.39716-39716, Article 39716

2017

Volltextzugriff (PDF)

Ultrathin Gold Microelectrode Array using Polyelectrolyte Multilayers for Flexible and Transparent Electro‐Optical Neural Interfaces

Advanced functional materials, 2022-02, Vol.32 (9), p.n/a

2022

Volltextzugriff (PDF)

Antibody-Positive Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome: Epidemiology and Outcome of Neuronal Antibody Testing in Sweden

Acta neurologica Scandinavica, 2023, Vol.2023, p.1-9

2023

Volltextzugriff (PDF)

Myasthenia Gravis and Physical Exercise: A Novel Paradigm

Frontiers in neurology, 2020-07, Vol.11, p.675-675

2020

Volltextzugriff (PDF)

Signaling and aging at the neuromuscular synapse: lessons learnt from neuromuscular diseases

Current opinion in pharmacology, 2012-06, Vol.12 (3), p.340-346

2012

Volltextzugriff (PDF)

miR-1933-3p is upregulated in skeletal muscles of MuSK+ EAMG mice and affects Impa1 and Mrpl27

Neuroscience research, 2020-02, Vol.151, p.46-52

2020

Volltextzugriff (PDF)

Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating microRNAs

Frontiers in immunology, 2020-02, Vol.11, p.151-151

2020

Volltextzugriff (PDF)

Reply to the Letter to the Editor in response to “Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal”

European journal of neurology, 2023-04, Vol.30 (4), p.1162-1164

2023

Volltextzugriff (PDF)

Novel pathogenic ALG2 mutation causing congenital myasthenic syndrome: A case report

Neuromuscular disorders : NMD, 2022-01, Vol.32 (1), p.80-83

2022

Volltextzugriff (PDF)

Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles: Special Considerations

Toxins, 2017-10, Vol.9 (11), p.352

2017

Volltextzugriff (PDF)

Lifestyle factors and disease‐specific differences in subgroups of Swedish Myasthenia Gravis

Acta neurologica Scandinavica, 2018-12, Vol.138 (6), p.557-565

2018

Volltextzugriff (PDF)

Keeping up appearances: Don’t frown upon the effects of botulinum toxin injections in facial muscles

Clinical neurophysiology practice, 2023-01, Vol.8, p.169-173

2023

Volltextzugriff (PDF)

Editorial: Advances in Autoimmune Myasthenia Gravis

Frontiers in immunology, 2020-08, Vol.11, p.1688-1688

2020

Volltextzugriff (PDF)

Botulinum toxin injections associated with suspected myasthenia gravis: An underappreciated cause of MG-like clinical presentation

Clinical neurophysiology practice, 2020-01, Vol.5, p.46-49

2020

Volltextzugriff (PDF)

Towards Personalized Medicine in Myasthenia Gravis: Role of Circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p

Cells (Basel, Switzerland), 2022-02, Vol.11 (4), p.740

2022

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(84)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders

Inflammatory and anti-inflammatory markers in plasma: from late pregnancy to early postpartum

Cancer in myasthenia gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies: A Swedish nationwide register study

Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study

Functional imaging of conduction dynamics in cortical and spinal axons

Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal

Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine

Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance‐based measures: A pilot study

Epidemiology of Myasthenia Gravis in Sweden 2006–2016

Myasthenia gravis patient and physician opinions about immunosuppressant reduction

Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients

Ultrathin Gold Microelectrode Array using Polyelectrolyte Multilayers for Flexible and Transparent Electro‐Optical Neural Interfaces

Antibody-Positive Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome: Epidemiology and Outcome of Neuronal Antibody Testing in Sweden

Myasthenia Gravis and Physical Exercise: A Novel Paradigm

Signaling and aging at the neuromuscular synapse: lessons learnt from neuromuscular diseases

miR-1933-3p is upregulated in skeletal muscles of MuSK+ EAMG mice and affects Impa1 and Mrpl27

Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating microRNAs

Reply to the Letter to the Editor in response to “Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal”

Novel pathogenic ALG2 mutation causing congenital myasthenic syndrome: A case report

Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles: Special Considerations

Lifestyle factors and disease‐specific differences in subgroups of Swedish Myasthenia Gravis

Keeping up appearances: Don’t frown upon the effects of botulinum toxin injections in facial muscles

Editorial: Advances in Autoimmune Myasthenia Gravis

Botulinum toxin injections associated with suspected myasthenia gravis: An underappreciated cause of MG-like clinical presentation

Towards Personalized Medicine in Myasthenia Gravis: Role of Circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p

Suchergebnisse filtern